{"id":7450,"date":"2021-12-16T08:00:31","date_gmt":"2021-12-16T13:00:31","guid":{"rendered":"https:\/\/puyapeptide.net\/product\/lanreotidiasetaatti-cas-127984-74-1-hoito-akromegaliaan-ja-oireisiin-neuroendokriinisiin-kasvaimiin\/"},"modified":"2021-12-16T08:00:31","modified_gmt":"2021-12-16T13:00:31","slug":"lanreotidiasetaatti-cas-127984-74-1-hoito-akromegaliaan-ja-oireisiin-neuroendokriinisiin-kasvaimiin","status":"publish","type":"product","link":"https:\/\/puyapeptide.net\/fi\/product\/lanreotidiasetaatti-cas-127984-74-1-hoito-akromegaliaan-ja-oireisiin-neuroendokriinisiin-kasvaimiin\/","title":{"rendered":"Lanreotidiasetaatti CAS 127984-74-1 Hoito akromegaliaan ja oireisiin neuroendokriinisiin kasvaimiin"},"content":{"rendered":"

Lanreotidiasetaatti CAS 127984-74-1 Hoito akromegaliaan ja oireisiin neuroendokriinisiin kasvaimiin<\/strong><\/h2>\n

Tuotteen nimi: Lanreotidiasetaatti
\nSynonyymit: 10-(4-aminobutyyli)-19-[(2-amino-3-naftalen-2-yylipropanoyyli)amino]-N-(1-karbamoyyli-2) -hydroksipropyyli)-16-[(4-hydroksifenyyli)metyyli]-13-(1 H-indol-3-yylimetyyli)-6,9,12,15,18-pentaokso-7-propan-2-yyli-1 ,2-ditia-5,8,11,14,17-pentatsasykloisaani-4-karboksamidi; somatuliini; LANREOTIDIASETATTI; 3-(2-naftalenyyli)-D-alanyyli-L-kysteinyyli-L-tyrosyyli-D-tryptofyyli- L-lysyyli-L-valyyli-L-kysteinyyli-L-treoniiniamidi, syklinen (2->7)-disulfidiasetaatti; angiopeptiiniasetaatti; 10-(4-aminobutyyli)-N-(1-amino-3-hydroksi-1-oksobutaani -2-yyli)-19-[(2-amino-3-naftalen-2-yylipropanoyyli)amino]-16-[(4-hydroksifenyyli)metyyli]-13-(1 H-indol-3-yylimetyyli)-6, 9,12,15,18-pentaokso-7-propan-2-yyli-1,2-ditia-5,8,11,14,17-pentatsasykloisaani-4-karboksamidi; Lanreotidiasetaatti USP\/EP\/BP
\n CAS: 127984-74-1
\nMF: C54H69N11O10S2
\nMW: 0
\nEINECS:
\nTuoteluokat: Aminohapot ja johdannaiset, l\u00e4\u00e4kkeet, v\u00e4lituotteet ja johdannaiset
\nMol File: 4-127-9 1.mol<\/p>\n

Lanreotidiasetaatti, oktapeptidi somatostatiini analoginen, saavutti ensimm\u00e4iset maailmanlaajuiset markkinansa akromegalialle Ranskassa, kun leikkaus tai s\u00e4dehoito eiv\u00e4t ole onnistuneet palauttamaan normaalia kasvuhormonin erityst\u00e4. Lanreotidi on kasvuhormonin selektiivinen est\u00e4j\u00e4 ja v\u00e4hent\u00e4\u00e4 kasvuhormonin, tyrotropiinin, motiliinin ja haiman polypeptidin erityst\u00e4 ihmisill\u00e4. Lanreotidilla on antiproliferatiivisia ominaisuuksia, ja sen kerrotaan olevan kliinisiss\u00e4 tutkimuksissa sepelvaltimon angioplastian j\u00e4lkeisen restenoosin ehk\u00e4isyyn, diabeettisen retinopatian hoitoon ja psoriaasin hoitoon. Sen potentiaali neuroendokriinisiin kasvaimiin ja hormoneihin reagoivaan eturauhassy\u00f6p\u00e4\u00e4n on my\u00f6s osoitettu.<\/p>\n

Lanreotide Acetate CAS 127984-74-1 Kemialliset ominaisuudet<\/strong>
\nvarastointil\u00e4mp\u00f6tila. -20\u00b0C
\njauheen muoto
\nv\u00e4ri valkoisesta luonnonvalkoiseen<\/p>\n

Lanreotidiasetaatin CAS 127984-74-1 toiminta ja k\u00e4ytt\u00f6<\/strong>
\nLanreotidiasetaatti, kuten luonnolliset kasvun est\u00e4j\u00e4t, lanreotidi on monien endokriinisten, neuroendokriinisten, eksokriinisten ja parakriinisten toimintojen peptidi-inhibiittori. Lanreotidi on aktiivisempi ja sen vaikutusaika on pidempi kuin luonnollisen kasvun est\u00e4j\u00e4t. Sen kasvuhormonin erityst\u00e4 est\u00e4v\u00e4 vaikutus on merkitt\u00e4v\u00e4sti selektiivisempi kuin insuliinin erityst\u00e4, ja vuonna 2017 FDA hyv\u00e4ksyi lanreotidiasetaatin injektiok\u00e4ytt\u00f6\u00f6n neuroendokriinisten kasvainten hoitoon.<\/p>\n","protected":false},"excerpt":{"rendered":"

Tuotteen nimi: Lanreotide Acetate
\nCAS: 127984-74-1
\nMF: C54H69N11O10S2
\nMol Tiedosto: 127984-74-1.mol<\/p>\n","protected":false},"featured_media":2100,"comment_status":"open","ping_status":"closed","template":"","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}}},"product_brand":[],"product_cat":[388],"product_tag":[2302],"class_list":{"0":"post-7450","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-kasvaimen-vastainen-peptidi","7":"product_tag-lanreotide-acetate-cas-127984-74-1-treat-for-acromegaly-and-symptomatic-neuroendocrine-tumors-fi","8":"desktop-align-left","9":"tablet-align-left","10":"mobile-align-left","12":"first","13":"instock","14":"shipping-taxable","15":"product-type-simple"},"_links":{"self":[{"href":"https:\/\/puyapeptide.net\/fi\/wp-json\/wp\/v2\/product\/7450","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/puyapeptide.net\/fi\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/puyapeptide.net\/fi\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/puyapeptide.net\/fi\/wp-json\/wp\/v2\/comments?post=7450"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/puyapeptide.net\/fi\/wp-json\/wp\/v2\/media\/2100"}],"wp:attachment":[{"href":"https:\/\/puyapeptide.net\/fi\/wp-json\/wp\/v2\/media?parent=7450"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/puyapeptide.net\/fi\/wp-json\/wp\/v2\/product_brand?post=7450"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/puyapeptide.net\/fi\/wp-json\/wp\/v2\/product_cat?post=7450"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/puyapeptide.net\/fi\/wp-json\/wp\/v2\/product_tag?post=7450"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}